Skip to main content

How can we help you?

  • Deal or case news
  • 20-05-2015


NautaDutilh has assisted clinical-stage biotech company Galapagos (Euronext Brussels and Euronext Amsterdam) on its 280mio EUR NASDAQ IPO, which closed in May 2015. The global offering was composed of a public offering in the United States of ordinary shares in the form of American Depositary Shares and a concurrent private placement of ordinary shares in Europe. Morgan Stanley, Credit Suisse and Cowen and Company acted as joint bookrunners. 

The transaction was a huge success: it is the largest biotech IPO on NASDAQ in recent years and the second largest ECM transaction to date in 2015 on Euronext Brussels. NautaDutilh acted as Belgian and Dutch counsel, alongside Goodwin Procter which acted as US counsel.

The team of NautaDutilh was headed by Nicolas de Crombrugghe and Christiaan de Brauw; the core team was composed of Philippine De Wolf, Louis Lantonnois, Paul van der Bijl and Philip Silvis.

Cookie notice

We care about your privacy. We only use cookies strictly necessary to ensure the proper functioning of our website. You can find more information on cookies and on how we handle your personal data in our Privacy and Cookie Policy.